Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 10/20 | 0.63 |
| ▸ | METAP1 | P53582 | 1/20 | 0.63 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.58 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 3/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22627332 | 0.80 | METAP2 (0.62) | METAP2METAP1NOTUMIDO1KEAP1 | |
| SCHEMBL28070596 | 0.78 | METAP2 (1.00) | METAP2METAP1NOTUMHAO1IDO1 | |
| SCHEMBL28741942 | 0.75 | METAP2 (0.56) | METAP2METAP1NOTUMIDO1KEAP1 | |
| SCHEMBL15660084 | 0.74 | METAP2 (0.64) | METAP2HAO1IDO1NPC1MAPT | |
| SCHEMBL28033548 | 0.74 | METAP2 (0.64) | METAP2METAP1NOTUMIDO1KEAP1 | |
| SCHEMBL104083 | 0.74 | METAP2 (0.64) | METAP2METAP1NOTUMIDO1KEAP1 | |
| SCHEMBL29626826 | 0.74 | METAP2 (1.00) | METAP2METAP1NOTUMHAO1IDO1 | |
| SCHEMBL8221447 | 0.73 | METAP2 (1.00) | METAP2METAP1NOTUMIDO1KEAP1 | |
| SCHEMBL13996093 | 0.73 | NPC1 (0.63) | IDO1NPC1MAPTMAPK1RAB9A | |
| SCHEMBL1186757 | 0.72 | AKT2 (0.57) | NPC1MAPTMAPK1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105062502-B | Liquid-crystal compounds and its preparation method and use containing penta azacyclo | 华南师范大学 | 2017-08-25 | — | — | CN | disclosed |
| CN-105062502-A | Liquid crystal compound containing five membered nitrogen-containing heterocycles, as well as synthesizing method and application thereof | UNIV SOUTH CHINA NORMAL | 2015-11-18 | — | — | CN | disclosed |
| US-7662779-B2 | Triazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662779-B2 | Triazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662779-B2 | Triazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2008021960-A2 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021960-A2 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, CTSC | METAP2 216/4885METAP1 93/4885NOTUM 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.